How the Helix Formulary Changes: What We Just Added, and What We Still Don't Offer

The Helix formulary is a living list, not a fixed menu. It recently expanded (adding BPC-157, TB-500, KPV, MOTS-c, Epitalon, and Semax after they advanced through the FDA's 503A review), while other peptides patients ask about remain off the list, for reasons of regulatory standing and evidence.

If you have spent any time researching peptides, you have a list. Names from forums, podcasts, and the accounts you follow. Some of those names have just become part of the Helix formulary. Others are still not on it. Rather than let either be a mystery, this article explains the reasoning directly, because a practice that tells you why it adds and declines is more trustworthy than one that just presents a menu.

The formulary is narrow on purpose, and it moves

Helix does not try to offer everything patients ask about. Two things determine whether Dr. Luria prescribes a given peptide: its regulatory standing and the evidence behind it. Regulatory standing means whether the peptide can be appropriately compounded by a licensed pharmacy under current federal rules, a status that, for peptides, has shifted meaningfully in recent years. Evidence means whether there is a meaningful clinical basis for its use, not just enthusiasm online.

A short formulary is not a limitation. It is the visible result of a practice declining to prescribe past what it can stand behind, and updating honestly when the landscape changes.

Because standing genuinely moves, the formulary moves with it. That is not indecision. It is the opposite: a practice paying close enough attention to change its list when the facts change.

What we recently added

In July 2026, the FDA's Pharmacy Compounding Advisory Committee reviewed a group of widely discussed peptides and issued recommendations bearing on their place in the 503A compounding framework. Following that process, and in coordination with the practice's pharmacy partner, Dr. Luria expanded the formulary to include six peptides that patients had long asked about:

• BPC-157 and TB-500: the recovery-and-repair peptides that travel together in soft-tissue and tissue-healing discussions.
• KPV: a small α-MSH-derived peptide studied for calming inflammatory signaling, with interest in gut and skin comfort.
• MOTS-c: a mitochondrial-derived peptide studied for metabolism and cellular energy.
• Epitalon: a pineal-derived peptide studied for sleep quality and healthy aging.
• Semax: an ACTH-derived peptide studied for focus and cognitive support.

A word of precision here, because it matters: these are compounded preparations, not FDA-approved finished drugs. An advisory-committee recommendation is a step in a process, not a guarantee, and Dr. Luria prescribes each one only after evaluating whether it fits an individual patient's goals and clinical picture. The addition reflects improved standing and patient interest, not a claim that any of them treats a disease.

What we still don't offer

Expanding the formulary did not turn it into an everything-menu. Several names patients raise remain off the list.

Melanotan II comes up in tanning conversations and, because of a structural resemblance, is sometimes confused with PT-141. It is not available through licensed US compounding pathways. If your underlying interest is a sexual-health protocol, that is a separate conversation: PT-141 (bremelanotide) is a different peptide Dr. Luria can discuss on its own terms.

Various cognitive and research peptides (for example Selank, or agents like Cerebrolysin) continue to lack an established US prescribing route or the evidence base Dr. Luria prescribes within. When that changes, the practice reassesses, exactly as it did with the peptides above.

Why we frame it this way

Notice what these explanations do and do not say.

They do not tell you the peptides still off the list are dangerous or that your research was foolish. Making safety pronouncements about medications a practice has not evaluated in you would be its own kind of overreach. Patients often arrive having read carefully, and that effort deserves respect.

What the explanations do say is narrower and more honest: a peptide is on the formulary when its regulatory standing and evidence clear the bar Helix prescribes within, and off it when they don't. That threshold is applied consistently: it is the same reason the list is short, the same reason it just grew, and the same reason it could change again.

The bottom line

Helix prescribes a deliberately narrow set of peptides, and it keeps that set current. The formulary recently expanded to include BPC-157, TB-500, KPV, MOTS-c, Epitalon, and Semax as their standing advanced; peptides like Melanotan II and Selank remain off it for now.

If a peptide you are curious about is not offered, the useful question is not "why won't you ever" but "what would have to change", and that is a question Dr. Luria can answer specifically in a consultation.

This article is educational and does not constitute medical advice, and reading it does not create a physician-patient relationship. Decisions about peptide therapy should be made in consultation with a licensed physician who has reviewed your individual health history. Medications prescribed through Helix are compounded preparations dispensed by Blue Atlas Pharmacy, a licensed 503A compounding pharmacy, under the prescription of Dr. Jamie Luria, MD. Compounded medications are not FDA-approved for safety, efficacy, or quality.